top of page

Leadership

Alex Li is a biopharma industry veteran. He has contributed to the success of several Multiple Sclerosis medicines, including Avonex, Plegridy, Tysabri, Vumerity and Ocrevus with two decades research experience in Biogen. Alex has also been deeply involved in the development of dapirolizumab pegol, a novel anti-CD40L drug to treat Lupus. He worked as COO in Axter Pharma for the past three years.
Alex received his Ph.D. (2000) in Biochem, Cellular and Molecular Biology (BCMA) from University of Tennessee, Knoxville (UTK). He also received Master of Business Management and Master of Science in Biochemistry from UTK, and his Bachelor in Biochemistry from Sichuan University (1989).
Alex Li
Chief Executive Officer (CEO)
bottom of page